Moderna Inc hMPV+PIV3 Interim Data Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the Moderna hMPV and PIV3 Interim Data Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to introduce your host for today's conference, Ms. Laura Schneck, Investor Relations at Moderna. Ma'am, you may begin.
Thank you, operator. Good afternoon, everyone, and thank you for joining us today to review the top-line interim clinical data from our Phase 1 study of mRNA-1653, our human metapneumovirus or hMPV and parainfluenza virus type 3 or PIV3 vaccine. You can access the press release for these data and the slides that we'll be reviewing by the going to the Investor section of our website at www.modernatx.com.
With me today are Stephane Bancel, our Chief Executive Officer; and Tal Zaks, our Chief Medical Officer. Lorence Kim, our Chief Financial Officer, is also here and will join us for Q&A
Before
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |